help button home button Am J Pathol R & D Systems
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Originally published online as doi:10.2353/ajpath.2008.070756 on March 18, 2008

Published online before print March 18, 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ajpath.2008.070756v1
172/4/868    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Ramanadham, S.
Right arrow Articles by Turk, J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ramanadham, S.
Right arrow Articles by Turk, J.
(American Journal of Pathology. 2008;172:868-881.)
© 2008 American Society for Investigative Pathology
DOI: 10.2353/ajpath.2008.070756

Age-Related Changes in Bone Morphology Are Accelerated in Group VIA Phospholipase A2 (iPLA2β)-Null Mice

Sasanka Ramanadham*, Kevin E. Yarasheski*, Matthew J. Silva{dagger}, Mary Wohltmann*, Deborah Veis Novack{ddagger}, Blaine Christiansen{dagger}, Xiaolin Tu{ddagger}, Sheng Zhang*, Xiaoyong Lei* and John Turk*

From the Medicine Department, Mass Spectrometry Facility, and Division of Endocrinology, Metabolism, and Lipid Research,* and the Departments of Orthopaedic Surgery{dagger} and Medicine,{ddagger} Division of Bone and Mineral Diseases, Washington University School of Medicine, St. Louis, Missouri

Phospholipases A2 (PLA2) hydrolyze the sn–2 fatty acid substituent, such as arachidonic acid, from phospholipids, and arachidonate metabolites are recognized mediators of bone modeling. We have previously generated knockout (KO) mice lacking the group VIA PLA2 (iPLA2β), which participates in a variety of signaling events; iPLA2β mRNA is expressed in bones of wild-type (WT) but not KO mice. Cortical bone size, trabecular bone volume, bone mineralizing surfaces, and bone strength are similar in WT and KO mice at 3 months and decline with age in both groups, but the decreases are more pronounced in KO mice. The lower bone mass phenotype observed in KO mice is not associated with an increase in osteoclast abundance/activity or a decrease in osteoblast density, but is accompanied by an increase in bone marrow fat. Relative to WT mice, undifferentiated bone marrow stromal cells (BMSCs) from KO mice express higher levels of PPAR-{gamma} and lower levels of Runx2 mRNA, and this correlates with increased adipogenesis and decreased osteogenesis in BMSCs from these mice. In summary, our studies indicate that age-related losses in bone mass and strength are accelerated in iPLA2β-null mice. Because adipocytes and osteoblasts share a common mesenchymal stem cell origin, our findings suggest that absence of iPLA2β causes abnormalities in osteoblast function and BMSC differentiation and identify a previously unrecognized role of iPLA2β in bone formation.








HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Society for Investigative Pathology.